A highly potent antibody effective against SARS-CoV-2 variants of concern | Zendy

Craig Fenwick | Zendy; Priscilla Turelli | Zendy; Laurent Perez | Zendy; Céline Pellaton | Zendy; Line Esteves-Leuenberger | Zendy; Alex Farina | Zendy; Jérémy Campos | Zendy; Erica Lana | Zendy; Flurin Fiscalini | Zendy; Charlène Raclot | Zendy; Florence Pojer | Zendy; Kelvin Lau | Zendy; Davide Demurtas | Zendy; Marc Descatoire | Zendy; Victor Joo | Zendy; Mathilde Foglierini | Zendy; Alessandra Noto | Zendy; Rana Abdelnabi | Zendy; Caroline S. Foo | Zendy; Laura Vangeel | Zendy; Johan Neyts | Zendy; Wenjuan Du | Zendy; BerendJan Bosch | Zendy; Geertruida M. Veldman | Zendy; Pieter Leyssen | Zendy; Volker Thiel | Zendy; R. Legrand | Zendy; Yves Lévy | Zendy; Didier Trono | Zendy; Giuseppe Pantaleo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A highly potent antibody effective against SARS-CoV-2 variants of concern

Author(s) -

Craig Fenwick,

Priscilla Turelli,

Laurent Perez,

Céline Pellaton,

Line Esteves-Leuenberger,

Alex Farina,

Jérémy Campos,

Erica Lana,

Flurin Fiscalini,

Charlène Raclot,

Florence Pojer,

Kelvin Lau,

Davide Demurtas,

Marc Descatoire,

Victor Joo,

Mathilde Foglierini,

Alessandra Noto,

Rana Abdelnabi,

Caroline S. Foo,

Laura Vangeel,

Johan Neyts,

Wenjuan Du,

BerendJan Bosch,

Geertruida M. Veldman,

Pieter Leyssen,

Volker Thiel,

R. Legrand,

Yves Lévy,

Didier Trono,

Giuseppe Pantaleo

Publication year - 2021

Publication title -

cell reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.264

H-Index - 154

eISSN - 2639-1856

pISSN - 2211-1247

DOI - 10.1016/j.celrep.2021.109814

Subject(s) - virology , antibody , monoclonal antibody , neutralizing antibody , covid-19 , pandemic , vaccination , biology , hamster , neutralization , immunology , medicine , microbiology and biotechnology , disease , infectious disease (medical specialty) , pathology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research